U.S. stock market update: Longevity Health down 7.54%

U.S. Stock Market Midday Update Longevity Health fell 7.54%, with increased trading volume. Based on recent important news: On July 23, Junyao Health experienced a block trade at a discount of 8.88%, leading to a 1.25% drop in stock price. On July 25, Meinian Health had a block trade at a discount of 6.73%, affecting market sentiment. On July 23, the AI wave pushed Taiwan's stock dividend expectations to exceed 2 trillion yuan, increasing market volatility. Stocks with High Trading Volume in the Industry Gilead Sciences rose 3.13%, with a trading volume of $652 million. Based on recent important news: On July 25, Gilead Sciences announced that its HIV-1 capsid inhibitor lenacapavir received a positive review from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending it for pre-exposure prophylaxis (PrEP), causing the stock price to rise by 2.31%. On July 25, Needham upgraded Gilead Sciences to "Buy," with a target price of $133, expecting Yeztugo sales to reach $6.4 billion by 2035, leading to an increase in stock price. On July 25, Gilead Sciences announced that its HIV prevention drug Lenacapavir officially launched in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, further boosting market confidence. AbbVie fell 0.02%, with increased trading volume. Based on recent important news: On July 24, AbbVie overcame the Humira patent cliff with Skyrizi and Rinvoq, expecting combined revenues to reach $24 billion by 2025, enhancing market confidence and stabilizing the stock price. On July 23, analysts believe AbbVie is not on the current best buy list, despite a rating of "Hold," affecting market sentiment. On July 24, AbbVie's strategic transformation in oncology and enhanced ADC capabilities improved the company's competitive position, keeping the stock price stable. Forte Pharmaceuticals fell 0.69%, with increased trading volume. Based on recent important news: On July 23, Forte Pharmaceuticals' competitor Vertex Pharmaceuticals announced that its cystic fibrosis treatment drug Alyftrek received market authorization in Canada, putting pressure on Forte Pharmaceuticals' stock price, which fell by 0.69%. On July 24, SK Hynix reported record quarterly profits driven by strong demand for AI chips, increasing market attention on AI-related stocks, which affected Forte Pharmaceuticals. On July 23, market interest in investments in AI and biotechnology increased, and Forte Pharmaceuticals' stock price fell due to its failure to achieve breakthroughs in this area Stocks Ranked Among the Top by Market Capitalization in the Industry Amgen fell 0.58%, with increased trading volume. Based on recent important news: On July 23, Bank of America raised Amgen's target stock price to $261, indicating increased market confidence in its future performance, leading to stock price fluctuations. On July 23, market analysis suggested that Amgen was not on the recommended buy list, resulting in insufficient investor confidence and pressure on the stock price. On July 23, the high prices of GLP-1 RA drugs and side effects affecting patient treatment adherence may impact the sales of Amgen's related products, causing stock price fluctuations